GLP-1 Medications for Weight Loss: A Medical Guide to Semaglutide, Tirzepatide, and What You Need to Know (2026)

Medically reviewed by the UTCardiothoracicSurgery.com editorial team | Published March 30, 2026 | Last updated March 30, 2026

Disclaimer: This article is for educational purposes only and doesn't constitute medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Don't start, stop, or change any medication without consulting your doctor. Individual results vary significantly based on health status, dosage, adherence, diet, and physical activity.

What Are GLP-1 Medications, and Why Is Everyone Talking About Them?

If you've been anywhere near a news feed, a doctor's office, or a family dinner table in the past two years, you've heard about GLP-1 medications for weight loss. Names like Ozempic, Wegovy, Mounjaro, and Zepbound have become household words — but for many people, the details remain confusing. Which one does what? Are they safe? Who actually qualifies? What's the difference between a brand name and a compounded version?

As a cardiothoracic surgery practice, we have a particular interest in these medications because obesity is one of the most significant modifiable risk factors for cardiovascular disease. The emergence of GLP-1 medications has fundamentally changed how we think about the relationship between weight management and heart health — and recent clinical trials have given us data that, frankly, we've been waiting decades to see.

This guide breaks down everything you need to know about GLP-1 weight loss medications in plain language: how they work, which medications are available, what the research actually shows, who qualifies, what the side effects look like, and what the cardiovascular evidence means. Whether you're considering these medications for yourself or just trying to make sense of the conversation, this is your starting point.

How GLP-1 Medications Work: The Biology in Plain English

GLP-1 stands for glucagon-like peptide-1, which is a hormone your body produces naturally in the gut after you eat. When GLP-1 is released, it does several things at once: it signals your brain that you're satisfied, it slows down how quickly food moves through your stomach so you feel full longer, and it helps your pancreas release the right amount of insulin to manage blood sugar.

Here's the catch — your body's natural GLP-1 only lasts a few minutes before enzymes break it down. It works while you're eating and shortly after, but the effects disappear quickly. That's where GLP-1 medications come in.

GLP-1 receptor agonists are synthetic versions of this hormone, engineered to resist those enzymes and last much longer — days instead of minutes. When you take a GLP-1 medication, you're essentially giving your body a sustained, amplified version of a signal it already knows how to respond to. The result is a powerful, consistent reduction in appetite, slower digestion, better blood sugar control, and — in many patients — significant weight loss that was previously achievable only through bariatric surgery.

The medications don't force you to stop eating. Instead, they turn down the volume on hunger signals and “food noise” — that constant background chatter in your brain about what to eat next, when to eat, and how much. Many patients describe it as finally feeling “normal” around food for the first time.

The GLP-1 Medications Available Right Now

One of the biggest sources of confusion is that the same molecules have multiple brand names depending on what they're approved to treat. Let's untangle that.

Semaglutide is a single molecule manufactured by Novo Nordisk. It's sold under three brand names:

Ozempic® — FDA-approved for type 2 diabetes and cardiovascular risk reduction. Given as a weekly injection. Maximum dose of 2 mg. Frequently prescribed off-label for weight loss, though that's not its manufactured in an FDA-registered facility and follows Good Manufacturing Practice (GMP) standards indication.

Wegovy® — FDA-approved specifically for chronic weight management and cardiovascular risk reduction. Same molecule as Ozempic, given as a weekly injection or a daily oral tablet (launched in early 2026). Higher maximum dose of 2.4 mg for injection.

Rybelsus® — FDA-approved for type 2 diabetes. An oral semaglutide tablet taken daily. Not FDA-approved for weight loss, though sometimes prescribed off-label for that purpose.

For a complete breakdown of how these three brands compare, including dosing, insurance, and clinical evidence, read our semaglutide deep-dive article.

Tirzepatide is a newer molecule manufactured by Eli Lilly. It's a dual agonist — meaning it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. That second hormone pathway adds extra metabolic benefits, which is why tirzepatide has shown greater average weight loss in head-to-head trials. It's sold under two brand names:

Mounjaro® — FDA-approved for type 2 diabetes. Given as a weekly injection.

Zepbound® — FDA-approved for chronic weight management and obstructive sleep apnea in patients with obesity. Same molecule as Mounjaro.

For the full tirzepatide explanation including how the dual mechanism works, see our tirzepatide guide. For a direct comparison of semaglutide versus tirzepatide on weight loss, blood sugar, heart health, and cost, read our head-to-head comparison.

What the Clinical Evidence Actually Shows

Let's talk numbers — because the clinical trial data for these medications is genuinely remarkable by historical standards.

Semaglutide (Wegovy): In the landmark STEP 1 trial involving 1,961 participants, patients taking 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks. About 69% of participants achieved at least 10% weight loss — a threshold associated with clinically meaningful improvements in blood pressure, cholesterol, blood sugar, and joint stress.

Tirzepatide (Zepbound): In the SURMOUNT-1 trial involving 2,539 participants, patients taking the highest dose of tirzepatide lost an average of 20.9% of their body weight over 72 weeks. The most direct head-to-head comparison, the SURMOUNT-5 trial, showed tirzepatide producing 20.2% average weight loss compared to 13.7% with semaglutide.

To put these numbers in context: before GLP-1 medications, the best non-surgical weight loss interventions typically produced 5-8% weight loss. Bariatric surgery produces 25-35% weight loss. GLP-1 medications have narrowed that gap significantly, giving patients a pharmaceutical option that approaches surgical results for many people.

For realistic expectations about timelines and what your first month on a GLP-1 looks like, the data shows most patients see meaningful appetite changes within the first 1-2 weeks, with significant weight loss becoming measurable over 3-6 months as doses are gradually increased.

GLP-1 Medications and Your Heart: The Cardiovascular Evidence

This is where our perspective as a cardiothoracic surgery practice becomes particularly relevant. The cardiovascular data for GLP-1 medications represents a genuine paradigm shift in how we think about weight management and heart disease.

The SELECT trial — which enrolled over 17,500 adults with established cardiovascular disease and overweight or obesity, but without diabetes — demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20% compared to placebo over approximately 40 months. Major adverse cardiovascular events include heart attack, stroke, and cardiovascular death. A 20% relative risk reduction is clinically significant by any standard.

This finding matters because obesity has long been recognized as an independent cardiovascular risk factor, yet pharmacological interventions for weight management historically lacked evidence of cardiovascular benefit. GLP-1 medications fundamentally changed that equation — they're now the first weight management medications to demonstrate actual heart protection in a rigorous clinical trial.

The cardiovascular benefits likely come from multiple interconnected mechanisms beyond just weight loss: direct anti-inflammatory effects on blood vessels, improvements in blood pressure and lipid profiles, reduced atherosclerosis progression, and improved cardiac function in patients with heart failure with preserved ejection fraction (HFpEF).

We explore this evidence in much greater depth — including what it means for patients with existing heart disease, heart failure considerations, and cardiac medication interactions — in our dedicated article on GLP-1 medications and heart health.

Who Qualifies for GLP-1 Medications?

According to FDA guidelines, GLP-1 medications for weight management are approved for adults with a body mass index (BMI) of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related medical condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease.

It's important to understand that FDA criteria and insurance coverage criteria aren't always the same thing. Many insurance plans have stricter requirements for weight loss medication coverage, sometimes requiring documented failure of supervised diet and exercise programs, specific BMI thresholds, or particular comorbidities. Coverage for GLP-1s prescribed for diabetes is generally broader than coverage for the same molecules prescribed for weight management.

GLP-1 medications are generally not recommended for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), a history of pancreatitis, severe gastrointestinal conditions such as gastroparesis, or those who are pregnant or planning to become pregnant.

For the complete eligibility breakdown including insurance navigation strategies, see our who qualifies guide.

Side Effects: What to Expect and What to Watch For

The most common side effects of GLP-1 medications are gastrointestinal — and they're common enough that you should expect them, particularly during the early weeks and after dose increases.

Common GI effects include nausea (affects 20-50% of patients depending on medication and dose), diarrhea, constipation, vomiting, and abdominal discomfort. For most patients, these symptoms are worst during the first few weeks and during dose escalation, then improve as the body adjusts. This is exactly why doctors use a gradual dose titration schedule rather than starting at the full dose.

Less common but serious risks include pancreatitis (inflammation of the pancreas), gallbladder problems, and potential thyroid concerns. The FDA requires a boxed warning about thyroid C-cell tumors based on animal studies, though this hasn't been confirmed in humans. Any severe, persistent abdominal pain should be evaluated promptly.

One side effect that gets less attention but deserves more: muscle loss alongside fat loss. When you lose weight rapidly through reduced calorie intake — whether from GLP-1 medications or any other cause — your body can break down muscle tissue along with fat. Adequate protein intake and resistance exercise are essential protective measures. We cover this in detail in our muscle loss prevention guide.

For the complete side effect breakdown including management strategies, cardiac-specific considerations, and drug interactions, see our comprehensive side effects guide.

Compounded vs. Brand-Name: A Crucial Distinction

With GLP-1 medications costing $900-1,400 per month at brand-name prices without insurance, many patients have turned to compounded versions — custom-prepared formulations from compounding pharmacies at a fraction of the cost (typically $179-299 per month).

This is an area where patients need to understand the regulatory landscape clearly. Compounded semaglutide is not FDA-approved. It hasn't undergone the same clinical trials for safety and effectiveness. The quality can vary between pharmacies. The FDA has raised specific concerns about some compounding pharmacies using salt forms of semaglutide (such as semaglutide acetate) rather than the semaglutide base used in FDA-approved products.

That doesn't necessarily mean compounded versions are unsafe — but it does mean the risk-benefit profile is less well-characterized. For patients who can't access or afford brand-name options, compounded semaglutide from a reputable, state-licensed compounding pharmacy represents a tradeoff between cost savings and regulatory certainty.

We break down this topic thoroughly — including what to look for in a compounding pharmacy, the FDA's specific concerns, and how to evaluate your options — in our compounded vs. brand-name guide.

The Cost Reality

Let's be direct about pricing, because cost is the single biggest barrier to access for many patients. Brand-name semaglutide (Ozempic or Wegovy) runs $900-1,400 per month without insurance. Brand-name tirzepatide (Mounjaro or Zepbound) is in a similar range. With insurance and manufacturer savings cards, some patients pay as little as $25 per month — but coverage varies enormously by plan, employer, and indication.

The oral Wegovy tablet launched in early 2026 at $149 per month through certain programs, significantly below previous self-pay prices for injectable semaglutide. Compounded semaglutide from telehealth providers typically runs $179-299 per month.

For the full cost breakdown including savings strategies, insurance navigation, patient assistance programs, and HSA/FSA eligibility, see our GLP-1 cost and access guide.

What Happens When You Stop?

This is the question that causes the most anxiety — and the honest answer is important. Research shows that most patients who stop GLP-1 medications regain a significant portion of lost weight within a year. In one clinical trial, patients who stopped tirzepatide regained approximately 14% of their body weight over the following 12 months, while those who continued treatment lost additional weight.

This doesn't mean the medications “don't work.” It means that obesity, for many people, is a chronic condition requiring ongoing management — similar to how blood pressure medications manage hypertension rather than curing it. The appetite, metabolic, and hormonal factors that drive weight gain don't disappear when you lose weight; they often reassert themselves when the medication that was suppressing them is removed.

Strategies for long-term maintenance, including lower maintenance doses, lifestyle modifications that improve weight retention, and the emerging evidence around who can successfully taper off, are covered in our stopping GLP-1 medications guide.

The Oral GLP-1 Revolution

For patients who don't want weekly injections, oral GLP-1 options are expanding rapidly. The Wegovy pill (oral semaglutide for weight management) became available in early 2026, and the OASIS clinical trial data showed comparable weight loss to the injectable form. Orforglipron, a non-peptide oral GLP-1 from Eli Lilly, is in late-stage clinical trials and could reach the market within the next 1-2 years.

Oral formulations come with their own considerations — particularly around absorption (they must be taken on an empty stomach with minimal water) and daily dosing rather than weekly injection. For a complete breakdown of oral GLP-1 options and what's coming next, see our oral GLP-1 pills guide.

Frequently Asked Questions

How quickly do GLP-1 medications start working?

Most patients notice reduced appetite within the first 1-2 weeks, even at the starting dose. Significant weight loss typically becomes measurable over 3-6 months as doses are gradually increased. Maximum weight loss in clinical trials occurred at 12-18 months of treatment.

Can my primary care doctor prescribe GLP-1 medications?

Yes. Any licensed healthcare provider — including primary care physicians, nurse practitioners, physician assistants, endocrinologists, and cardiologists — can prescribe GLP-1 medications. You don't need to see a specialist, though working with a provider experienced in weight management can improve outcomes.

Do GLP-1 medications interact with heart medications?

GLP-1 medications have no concerning interactions with most cardiovascular medications including statins, ACE inhibitors, ARBs, beta-blockers, or calcium channel blockers. However, the delayed gastric emptying caused by GLP-1s may theoretically affect absorption of some oral medications. Discuss your complete medication list with your prescriber. Our cardiovascular guide covers cardiac drug interactions in detail.

Is compounded semaglutide the same as Ozempic?

No. While reputable compounded versions contain semaglutide base (the same active ingredient), they haven't undergone FDA review for safety, effectiveness, or manufacturing quality. The formulation, inactive ingredients, and quality controls may differ. See our compounded vs. brand-name guide for the full breakdown.

Will I need to take these medications forever?

That depends on your individual situation. Current evidence suggests that many patients regain weight when they stop GLP-1 medications, similar to how blood pressure rises when antihypertensive medications are discontinued. Some patients may be able to maintain weight loss with lower doses or lifestyle modifications alone, but this is an active area of research. See our stopping medications guide.

What's the difference between Ozempic and Wegovy?

They contain the exact same molecule — semaglutide. Ozempic is manufactured in an FDA-registered facility and follows Good Manufacturing Practice (GMP) standards for type 2 diabetes (maximum dose 2 mg). Wegovy is manufactured in an FDA-registered facility and follows Good Manufacturing Practice (GMP) standards for weight management (maximum dose 2.4 mg for injection). Insurance coverage and pricing may differ based on the approved indication. See our semaglutide explainer for the complete breakdown.

Are GLP-1 medications safe for people with heart disease?

For most patients with cardiovascular disease, GLP-1 medications aren't just safe — they may be beneficial. The SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide. However, patients with heart failure with reduced ejection fraction (HFrEF) have less established evidence, and earlier studies raised some concerns. Any patient with cardiovascular disease should have this conversation with their cardiologist. See our heart health guide.

Where to Start

If you're considering GLP-1 medications, here's our recommended reading path through this educational series:

Step 1: You're here. This guide gives you the foundation.

Step 2: Read about the specific medication that interests you — semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) — or go straight to the head-to-head comparison.

Step 3: Check our eligibility and insurance guide to understand whether you qualify and what you might pay.

Step 4: Review the side effects guide so you know what to expect.

Step 5: If you have cardiovascular concerns, our heart health article is essential reading.

At UT Cardiothoracic Surgery, we believe that informed patients make better health decisions. GLP-1 medications represent a genuine breakthrough in weight management — but like any medical treatment, they work best when patients understand what they're taking, why it works, what to expect, and what questions to ask their healthcare provider.

This article is part of our educational series on GLP-1 medications and cardiovascular health. For our clinical perspective on specific GLP-1 programs and their cardiac safety profiles, see our SynergyRx GLP-1 and Cardiovascular Health article.

This article will be updated as new research and FDA actions become available. Last reviewed: March 30, 2026.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.